These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29363389)

  • 1. Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-Life Versus Extended Half-Life Products and Those Switching from Standard Half-Life to Extended Half-Life Products.
    Tortella BJ; Alvir J; McDonald M; Spurden D; Fogarty PF; Chhabra A; Pleil AM
    J Manag Care Spec Pharm; 2018 Jul; 24(7):643-653. PubMed ID: 29363389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States.
    Aledort L; Milligan S; Watt M; Booth J
    J Manag Care Spec Pharm; 2020 Apr; 26(4):492-503. PubMed ID: 32223610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Amount of Clotting Factor Concentrates Dispensed and Annual Medical Expenditures for Japanese Patients with Hemophilia B.
    Fukutake K; Togo K; Xu L; Markson LE; Alvir JMJ; Winburn I; Karumori T
    J Blood Med; 2023; 14():649-661. PubMed ID: 38143791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors.
    Pochopien M; Tytuła A; Toumi M; Falk A; Martone N; Hakimi Z; Eriksson D
    Adv Ther; 2024 Jun; 41(6):2307-2323. PubMed ID: 38652439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Amount of Clotting Factor Products and Non-Factor Products Dispensed and Annual Medical Expenditures for Japanese Patients with Haemophilia A.
    Bingo M; Fukutake K; Togo K; Xu L; Alvir JMJ; Winburn I; Karumori T
    Drugs Real World Outcomes; 2024 Sep; 11(3):541-552. PubMed ID: 39127822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2021 Nov; 81(17):2035-2046. PubMed ID: 34743314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B.
    Koopman SF; Goedhart TMHJ; Bukkems LH; Mulders TM; Leebeek FWG; Fijnvandraat K; Coppens M; Mathias M; Collins PW; Tait RC; Bagot CN; Curry N; Payne J; Chowdary P; Cnossen MH; Mathôt RAA;
    Br J Clin Pharmacol; 2024 Jan; 90(1):220-231. PubMed ID: 37567779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor IX Fc for the treatment of hemophilia B.
    Ljung R; Matino D; Shapiro AD
    Eur J Haematol; 2024 May; 112(5):678-691. PubMed ID: 38369860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
    Guillet B; Yan S; Hooper B; Drelich D; Steenkamp J; Tomic R; Mancuso ME
    Adv Ther; 2024 Feb; 41(2):649-658. PubMed ID: 38070040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and Management of Bleeding Episodes in Children with Hemophilia.
    Ljung RCR
    Paediatr Drugs; 2018 Oct; 20(5):455-464. PubMed ID: 30128815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting.
    Ay C; Perschy L; Rejtö J; Kaider A; Pabinger I
    Ann Hematol; 2020 Dec; 99(12):2763-2771. PubMed ID: 32918114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX-Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective-Prospective Study.
    Coppola A; Rivolta GF; Quintavalle G; Matichecchia A; Riccardi F; Rossi R; Benegiamo A; Ranalli P; Coluccio V; Tagliaferri A
    J Clin Med; 2024 Mar; 13(5):. PubMed ID: 38592343
    [No Abstract]   [Full Text] [Related]  

  • 13. Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B.
    Shapiro AD; Kulkarni R; Ragni MV; Chambost H; Mahlangu J; Oldenburg J; Nolan B; Ozelo MC; Foster MC; Willemze A; Barnowski C; Jain N; Winding B; Dumont J; Lethagen S; Barnes C; Pasi KJ
    Blood Adv; 2023 Jul; 7(13):3049-3057. PubMed ID: 36848635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Haemophilia B therapy: impact of the reimbursability of a long-acting recombinant factor on pharmaceutical expenditure in Italy].
    Marano G; Capannini E; Annunziata A; Trotta F; Da Cas R; Mucci L
    Epidemiol Prev; 2024; 48(3):233-238. PubMed ID: 38995136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.
    Meier N; Fuchs H; Galactionova K; Hermans C; Pletscher M; Schwenkglenks M
    Pharmacoecon Open; 2024 May; 8(3):373-387. PubMed ID: 38520664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.
    Klamroth R; Bonner A; Gomez K; Monahan PE; Szafranski K; Zhang X; Walsh S; Wang D; Yan S
    Haemophilia; 2024 Jan; 30(1):75-86. PubMed ID: 37902714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a recombinant factor IX molecule fused to coagulation factor XIII-B subunit.
    Desage S; Leuci A; Enjolras N; Holle LA; Singh S; Delavenne X; Wolberg AS; Biswas A; Dargaud Y
    Haemophilia; 2023 Nov; 29(6):1483-1489. PubMed ID: 37707428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data.
    Farahbakhshian S; Fan Q; Schultz BG; Princic N; Park J; Bullano M
    J Med Econ; 2023; 26(1):1278-1286. PubMed ID: 37787429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review.
    Pasca S; Zanon E
    Drug Des Devel Ther; 2022; 16():3109-3116. PubMed ID: 36132333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review.
    Ay C; Napolitano M; Hassoun A; Tomic R; Martin C; Seifert W; Pinachyan K; Oldenburg J
    Haemophilia; 2024 May; 30(3):577-588. PubMed ID: 38549463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.